Nanolipogel (NLG) technology, invented in the lab of Dr. Tarek Fahmy at Yale University, allows different combinations of drugs to be encapsulated in a single nanomedicine and delivered selectively to the tumor microenvironment, thus potentially minimizing systemic side-effects. NLG technology possesses the unusual feature of accommodating drugs with very different physical and chemical properties, thus allowing them to be transported to, and released, at the disease site in a coordinated manner. Saugatuck Therapeutics Ltd (“Saugatuck”) which has acquired an exclusive license from Yale University for use of the NLG platform for delivering DNA aptamers and certain aptamer-based combination products.
SalvaRx has also signed a letter of intent with D5 Pharma Inc. (“D5”), a Toronto-based company spun out of the Sunnybrook Research Institute, which shall provide Saugatuck with an anti-PD1 aptamer for initial pilot animal experiments in the NLG formulation. Subject to certain milestones being met, including the results of the experiments, SalvaRx will invest in D5 and also form Oncomer Limited, (“Oncomer”) a new company that will have the rights to use D5’s aptamer creation platform for use in immuno-oncology applications.
Ian B. Walters, M.D., M.B.A., is the Entrepreneur in Residence at Mediqventures and is part-time CMO of Intensity Therapeutics, Inc. Over his 16 year career, he has demonstrated both leadership and expertise in drug development, including the advancement of multiple cancer compounds from research stages through approval.
Ian specialises in the evaluation, prioritization, and the innovative development of new therapies for the treatment of severe diseases. He has worked at PDL BioPharma, Inc., Millenium Pharmaceuticals, Inc., and Sorrento Therapeutics, Inc., leading corporate development, translational medicine, clinical development and medical affairs.
Ian spent seven years at Bristol-Myers Squibb, where he managed physicians overseeing the international development of more than eight oncology compounds (including Nivolimab (anti-PD-1), Ipilimumab (anti-CTLA-4), brivanib (anti VEGF/FGF), anti-IGF/IR, VEGFR2 biologic, Elotuzimab (antiCS1), as well as biomarker and companion diagnostic work. He was a core member of Bristol- Myers Squibb’s Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions, clinical collaborations, and the company’s immuno-oncology strategy.
Before entering the private sector, Ian was a lead investigator at the Rockefeller University and initiated advanced immunology research to understand the mechanism of action of several compounds. Ian received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of The University of Pennsylvania.
Mark Moody, Ph.D. Has more than twenty years of industry experience in multiple areas of drug development, including process/analytical development, manufacturing, toxicology, regulatory, and clinical development. Concurrently he serves as the COO of Immunova, the company that developed the NLG technology. Prior to Saugatuck, he served in a variety of roles at Merrimack Pharmaceuticals, including Vice President of Manufacturing and Vice President of Analytical Science, where he provided strategic guidance and tactical management for all activities required for the cGMP manufacturing and analysis of Merrimack’s portfolio of biologic and nano-liposome products, including Onivyde, a liposomal formulation of irinotecan recently approved by the FDA for pancreatic cancer. Prior to joining Merrimack, Dr. Moody was the Director of Research at Pierce Chemical’s Boston Technology Center where he led the development and commercialization of new technologies for drug discovery, including mRNA quantification assays and microtiter plate-based antibody arrays. Dr. Moody was trained as a Postdoctoral Fellow in the Department of Microbiology and Immunology at Duke University, and earned his Ph.D. in the Department of Microbiology at the University of Georgia.
Linda retired from Bristol-Myers Squibb (BMS) as Vice President and Head of Immuno-Oncology/Oncology Product & Portfolio Strategy and Opdivo and Yervoy Life Cycle Management. Prior to that role, she was the commercial lead for Opdivo (Nivolumab) and was instrumental in helping BMS develop its clinical and commercial strategy for Immunology-Oncology, which included combinations with BMS I-O assets and acquisition of external molecules. Ms. Kozick received her Bachelor of Science and Master of Science degrees from Upstate Medical Center, and her Master’s in Business Administration from Chapman University.